Venus Remedies Ltd Announces Q1 Results; Approves Revisions to Memorandum of Association
Venus Remedies Limited announced the Unaudited Financial Results for the quarter ended June 30, 2026, and approved key revisions to its Memorandum of Association (MOA) during a Board meeting held on July 20, 2026. The company's financial performance and strategic updates were reviewed by the statutory auditor.The management approved the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026. Concurrently, the Board of Directors approved revisions to the proposed alteration of the Memorandum and Articles of Association (MOA and AOA).
The amendments to the MOA were made primarily to align the Company's Object Clause with the provisions of the Companies Act, 2013. The revisions update the Main Objects and Incidental or Ancillary Objectives to reflect the Company’s current business practices and proposed activities. While the object clause has been updated for greater clarity, the principal business activities of Venus Remedies remain in the pharmaceutical sector.
Financial Highlights for the Quarter Ended June 30, 2026
The results reflected both consolidated and standalone figures. Key financial data is presented below:| Metric | Consolidated Results (Rs. in Crores) | Standalone Results (Rs. in Crores) |
|---|---|---|
| Total Income | 181.48 | 181.35 |
| Total Expenses | 151.44 | 206.08 |
| Profit Before Taxes (PBT) | 30.04 | 32.60 |
| Net Profit/(Loss) for the Period | 22.97 | 25.53 |
The Company's consolidated results include the performance of its subsidiaries, Venus Pharma GmbH and Venus Pharma Kft. The financial information pertaining to these foreign-based entities has been reviewed by auditors under applicable standards.
International Operations and Investment Status
The review reports noted that the parent company holds a wholly owned subsidiary in Germany, Venus Pharma GmbH, and a step down subsidiary, Venus Pharma Kft.The results highlight certain aspects concerning the investment in the German subsidiary. The audit findings state that the share allotment against the outstanding application money amounting to INR 2,859.72 Lakhs for Venus Pharma GmbH is still pending, as such allotment is not mandated under the applicable laws of Germany.
Management has stated that it views this investment as strategic and intends to recover this amount in due course through the restructuring of European operations planned for FY 2026-27, providing necessary financial and operational support during the transition period.
Subsidiary Performance Details
The standalone results include the unaudited interim financial results of two international subsidiaries:| Name of Subsidiary | Revenue (INR in Crores) | Net Profit/(Loss) (INR in Crores) |
|---|---|---|
| Venus Pharma GmbH | 2.08 | (2.55) |
| Venus Pharma Kft | Nil | Nil |
The Consolidated Financial Results, prepared in accordance with Indian Accounting Standard 34 and reviewed by the statutory auditors, confirm that the group operates solely within the 'Pharmaceuticals' segment.
VENUSREM Stock Price Movement
Today, shares of Venus Remedies Limited shed 4.96% to settle at ₹1682.20 after trading activity. The stock was traded a total of 67,333 shares during the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: